Beyond patents: Effective intellectual property strategy in biotechnology

Therese Seldon
University of Queensland, Brisbane QLD

PP: 055 - 061

Abstract

Dispelling the linear view of intellectual property protection in biotechnology, intellectual property (IP) and patents are almost synonymous in the biotechnology industry. In this innovation-intensive industry, it is unsurprising that patents are the foremost means of protection, since they provide (at least) 20 years exclusivity.

However, a recent seven-year international study challenged the preconception that patenting leads to heightened innovation (International Expert Group on Biotechnology 2008). The following analysis uses case studies to demonstrate that leading companies take a holistic approach to IP management.

| More

Keywords

intellectual property; IP strategy; value extraction; patents; open innovation; Athlomics

View references

References

Affymetrix Inc. (2009) Accessed at www.affymetrix.com/about_affymetrix/legal/patents.affx#1_2 on 25 April 2010.

Anonymous. (1988) BRL734: Genentech charges Invitron and Monsanto in trade secret suit, Biotechnology Law Report 7: 10-69.

Arena, C. and Carreras, E. (2008) The business of intellectual property, Oxford University Press, New York.

Baker, M. (2005) Upping the ante on antibodies, Nature Biotechnology 23: 1065-1072.

Barratt, B. (2003) Defensive use of publications in an intellectual property strategy, Bioentrepreneur 20: 191-193.

Bigelow, B. (2010) San Diego's Sequenom steps back into the spot light, sort of, Xconomy. com, accessed http://www.signonsandiego.com/news/2010/apr/04/wwwxconomycom68896/ on 30 April 2010.

Chandwani, R. and Portman, S. (2004) Riding the risk cycle, Nature Biotechnology 22: 1187-1188.

Chesbrough, H. (2003) Open innovation: The new imperative for creating and profiting from technology, Harvard Business School Press, Boston.

Clark, V. (2004) Pitfalls in drafting royalty provisions in patent licences, Bio-science Law Review, accessed http://pharmalicensing.com/public/articles/view/1087832097_40d70021d738c on 29 October 2009.

Fetterhoff, T. and Voelkel, D. (2006) Managing open innovation in biotechnology, Research Technology Management 49(3): 14-18.

Greis, N., Dibner, M. and Bean, A. (1995) External partnering as a response to innovation barriers and global competition in biotechnology, Research Policy 24: 609-630.

Grönwall, C. and Ståhl, S. (2009) Engineered affinity proteins for tumour targeting applications, Journal of Biotechnology 140: 254-269.

Howard, K. (2004) Global biotech expansion taking cues from Bayh-Doyle, Nature Biotechnology 22(7): 919-920.

Huggett, B. (2008) Big pharma swallows biotech's pride, Nature Biotechnology 26(9): 955-956.

Huston, L. and Sakkab, N. (2006) Connect and develop: Inside Procter & Gamble's new model for innovation, Harvard Business Review 84(3): 58-66.

International Expert Group on Biotechnology, Innovation and Intellectual Property (2008) Toward a new era of intellectual property: From confrontation to negotiation, McGill Centre for Intellectual Policy, Montreal.

Judson, E. and Dapprich, J. (2009) Negotiation 2.0, Nature Biotechnology 27: 1-3.

Li, W. and Xiang, Y. (2007) Patents: Patent strategies for biotechnology enterprises, BioPharm International 20: 56-57.

Lehrman, S. (1997) Abbott sues Chiron over 'secrets' in heads of recruits, Nature 385: 760.

Lott. (2002) Lott v, J. B. W. & Friends P/L & Endeavour Corp Design No. SCGRG-99-679 SASC3.

Matthie, J. (2008) Bioimpedance measurements of human body composition: Critical analysis and outlook, Expert Reviews Medical Devices 5(2): 239-261.

Melese, T. (2009) Open innovation networks between academia and industry: An imperative for breakthrough therapies, Nature Medicine 15(5): 502-507.

Sapienza, A. and Lombardino, J. (2002) Recognizing, appreciating, and capturing the tacit knowledge of R&D scientists, Drug Development Research 57: 51-57.

Waltz, E. (2009) Genentech's Cabilly victory, Nature Biotechnology 27(4): 307.

Williamson, A. (1999) The Merck gene index project, Drug Discovery Today 4(3): 115-122.

Zhang, P. (2010) Around the block. Nature Biotechnology, 28: 1239-1241.

Navigate: Archives | Contents | Top of page

Sign Me Up

*Email Address
First Name
Surname

Web Feed

Latest Articles

Special Issues

Collaborative and Challenge-led Innovation
Volume 14/2
Summary | Contents

Public Sector Innovation
Volume 12/2
Summary | Contents

Network Analysis Application in Innovation Studies
Volume 12/1
Summary | Contents

Innovation Policy in the Creative Industries
Volume 11/2
Summary | Contents

Innovation and the City – Innovative Cities
Volume 10/2-3
Summary | Contents

Food-related Innovation: Technology, Genetics and Consumer Impacts
Volume 10/1
Summary | Contents

Nurturing the Knowledge Tree: CSIRO in Australia's Innovation Systems
Volume 9/2
Summary | Contents

Innovation in China: Harmonious Transformation?
Volume 8/1-2
Summary | Contents

Innovation and Economic Development: Lessons from Latin America
Volume 7/2-3
Summary | Contents

Biotechnology and Telecommunications: Conditions and Processes for Emerging Technologies
Volume 7/1
Summary | Contents

Corporate Sustainability: Governance, Innovation Strategy, Development and Methods
Volume 6/2
Summary | Contents

Asia Pacific Innovation Readings
Volume 4/1-3
Summary | Contents

crossref.org - The citation linking backbone



Website by Arrowsmith Websites Sunshine Coast. Business & Government Websites, Social Media, Web Hosting, Domain Names & SEO. Website Design Sunshine Coast, Australia.